Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Cyclophosphamide Toxicity in Pediatric Nephrotic Syndrome Patient: A Case Report and Literature Review

Author(s): Soumya Patil, Mahantesh V Patil, Apoorva Bagalkotkar and Shashikala Wali*

Volume 19, Issue 4, 2024

Published on: 09 January, 2024

Page: [489 - 496] Pages: 8

DOI: 10.2174/0115748863281214231213075642

Price: $65

Abstract

Background: Primary membranous nephropathy is a rare presentation in children. Patients unresponsive to steroids and experiencing frequent relapse are considered steroid-resistant. They often require complex treatment regimens consisting of immunosuppressants like cyclophosphamide, tacrolimus, and cyclosporin A.

Case: In the present case, a 5-year-old child was suffering from steroid-resistant nephrotic syndrome for the past 10 months. He was initially treated with prednisolone 20mg but was subsequently found to be steroid-resistant. A renal biopsy revealed primary podocytopathy with immunocomplex deposits in podocyte tissues, suggesting primary membranous nephropathy as the cause of SRNS (steroid-resistant nephrotic syndrome). Cyclophosphamide 25mg twice daily was added to the treatment plan since the child did not tolerate tacrolimus therapy. During a subsequent follow-up, the physician reduced the cyclophosphamide 25mg dose to once a day, but parents misinterpreted this, and the child received a larger dose, cyclophosphamide 25mg, four times a day for 20 days. This resulted in cyclophosphamide toxicity-induced neutropenia, alopecia and posing the child at greater risk of sepsis.

Conclusion: Nephrotic syndrome is a chronic disease that demands extensive treatment plans and strict monitoring. Medication errors are common among parents or caregivers of pediatric patients. This case is a take-home message emphasizing the significance of patient-centered communication in preventing medication errors. A clinical pharmacist can aid in conveying simple and unambiguous information to parents or caregivers.

« Previous Next »
Graphical Abstract

[1]
Lane JC, Kaskel FJ. Pediatric nephrotic syndrome: From the simple to the complex. InSeminars in nephrology 2009; 29(4): 389-98.
[http://dx.doi.org/10.1016/j.semnephrol.2009.03.015]
[2]
Londeree J, McCracken CE, Greenbaum LA, et al. Estimation of childhood nephrotic syndrome incidence: Data from the atlanta metropolitan statistical area and meta-analysis of worldwide cases. J Nephrol 2022; 35(2): 575-83.
[http://dx.doi.org/10.1007/s40620-021-01108-9] [PMID: 34213762]
[3]
Zhao J, Liu Z. Treatment of nephrotic syndrome: Going beyond immunosuppressive therapy. Pediatr Nephrol 2020; 35(4): 569-79.
[http://dx.doi.org/10.1007/s00467-019-04225-7] [PMID: 30904930]
[4]
Sinha A, Bagga A. Clinical practice guidelines for nephrotic syndrome: Consensus is emerging. Pediatr Nephrol 2022; 37(12): 2975-84.
[http://dx.doi.org/10.1007/s00467-022-05639-6] [PMID: 35763086]
[5]
Sinha A, Bagga A, Banerjee S, et al. Steroid sensitive nephrotic syndrome: Revised guidelines. Indian Pediatr 2021; 58(5): 461-81.
[http://dx.doi.org/10.1007/s13312-021-2217-3] [PMID: 33742610]
[6]
Kidney Disease: Improving global outcomes (KDIGO) glomerular diseases work group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021; 100: 1-276.
[7]
Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361(1): 11-21.
[http://dx.doi.org/10.1056/NEJMoa0810457] [PMID: 19571279]
[8]
Durkan AM, Hodson EM, Willis NS, Craig JC. Immunosuppressive agents in childhood nephrotic syndrome: A meta-analysis of randomized controlled trials. Kidney Int 2001; 59(5): 1919-27.
[http://dx.doi.org/10.1046/j.1523-1755.2001.0590051919.x] [PMID: 11318964]
[9]
Beanlands H, Maione M, Poulton C, et al. Learning to live with nephrotic syndrome: Experiences of adult patients and parents of children with nephrotic syndrome. Nephrol Dial Transplant 2017; 32 (Suppl. 1): i98-i105.
[http://dx.doi.org/10.1093/ndt/gfw344] [PMID: 28391342]
[10]
Lopez-Pineda A, Gonzalez de Dios J, Guilabert Mora M, Mira-Perceval Juan G, Mira Solves JJ. A systematic review on pediatric medication errors by parents or caregivers at home. Expert Opin Drug Saf 2022; 21(1): 95-105.
[http://dx.doi.org/10.1080/14740338.2021.1950138] [PMID: 34251951]
[11]
Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 1978; 13(2): 159-65.
[http://dx.doi.org/10.1038/ki.1978.23] [PMID: 713276]
[12]
Cossey LN, Walker PD, Larsen CP. Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy. Pediatr Nephrol 2013; 28(12): 2307-11.
[http://dx.doi.org/10.1007/s00467-013-2574-9] [PMID: 23903693]
[13]
Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 2017; 28(10): 3055-65.
[http://dx.doi.org/10.1681/ASN.2016101121] [PMID: 28566477]
[14]
Vasudevan A, Thergaonkar R, Mantan M, et al. Consensus guidelines on management of steroid-resistant nephrotic syndrome. Indian Pediatr 2021; 58(7): 650-66.
[http://dx.doi.org/10.1007/s13312-021-2262-y] [PMID: 33408286]
[15]
Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol 2009; 6(11): 638-47.
[http://dx.doi.org/10.1038/nrclinonc.2009.146] [PMID: 19786984]
[16]
Langford CA. Complications of cyclophosphamide therapy. Eur Arch Otorhinolaryngol 1997; 254(2): 65-72.
[http://dx.doi.org/10.1007/BF01526181] [PMID: 9065658]
[17]
Mitra S, Banerjee S. The impact of pediatric nephrotic syndrome on families. Pediatr Nephrol 2011; 26(8): 1235-40.
[http://dx.doi.org/10.1007/s00467-011-1841-x] [PMID: 21626223]
[18]
Solanki R, Mondal N, Mahalakshmy T, Bhat V. Medication errors by caregivers at home in neonates discharged from the neonatal intensive care unit. Arch Dis Child 2017; 102(7): 651-4.
[http://dx.doi.org/10.1136/archdischild-2016-311877] [PMID: 28468867]
[19]
Sil A, Sengupta C, Das A, Sil P, Datta S, Hazra A. A study of knowledge, attitude and practice regarding administration of pediatric dosage forms and allied health literacy of caregivers for children. J Family Med Prim Care 2017; 6(3): 636-42.
[http://dx.doi.org/10.4103/2249-4863.214433] [PMID: 29417022]
[20]
Velez LI, Feng SY, Neerman MF. A dispensing error resulting in possible fluoxetine overdose and subsequent discontinuation syndrome in a child. Clin Pediatr 2010; 49(11): 1072-4.
[http://dx.doi.org/10.1177/0009922810366734] [PMID: 20522613]
[21]
Aburawi EH, Narchi H, Souid AK. Persistent wandering atrial pacemaker after epinephrine overdosing: A case report. BMC Pediatr 2013; 13(1): 1-3.
[http://dx.doi.org/10.1186/1471-2431-13-1] [PMID: 23281628]
[22]
Barbuto AF, Burns MM. Clonidine compounding error: Bradycardia and sedation in a pediatric patient. J Emerg Med 2020; 59(1): 53-5.
[http://dx.doi.org/10.1016/j.jemermed.2020.04.027] [PMID: 32389431]
[23]
D’Alessandro LCA, Rieder MJ, Gloor J, Freeman D, Buffo-Sequiera I. Life-threatening flecainide intoxication in a young child secondary to medication error. Ann Pharmacother 2009; 43(9): 1522-7.
[http://dx.doi.org/10.1345/aph.1L549] [PMID: 19671803]
[24]
Borek HA, Charlton NP. Accidental pediatric paliperidone ingestion resulting in delayed profound tachycardia. J Emerg Med 2019; 57(4): e109-11.
[http://dx.doi.org/10.1016/j.jemermed.2019.06.049] [PMID: 31591075]
[25]
André MC, Hammer J. Life-threatening accidental intravenous epinephrine overdose in a 12-year-old boy. Pediatr Emerg Care 2019; 35(6): e110-2.
[http://dx.doi.org/10.1097/PEC.0000000000001407] [PMID: 29406471]
[26]
Brener P, Ballardo M, Mariani G, Ceriani Cernadas JM. Medication error in an extremely low birth weight infant: Paracetamol overdose. Arch Argent Pediatr 2013; 111(1): 53-5.
[PMID: 23381705]
[27]
Green AL, Srivatsa A, Rodriguez-Galindo C. Delayed diagnosis and false relapse due to paternal testosterone use in adrenocortical carcinoma. Pediatrics 2014; 133(6): e1772-6.
[http://dx.doi.org/10.1542/peds.2013-1454] [PMID: 24799542]
[28]
Friedman BT, Chen BC, Latimer AJ, Valento MJ. Iatrogenic pediatric hydroxocobalamin overdose. Am J Emerg Med 2019; 37(7): 1394.e1-2.
[PMID: 31000316]
[29]
Tsai PB, Bergin MW. Unintentional infiltration of high dose epinephrine in an infant: A case report. A A Pract 2020; 14(6): e01179.
[http://dx.doi.org/10.1213/XAA.0000000000001179] [PMID: 32224687]
[30]
Kwan D, Vohra R, Dyer JE, Dornhoffer P. An infant with a heartbreaking medication error. Pediatr Emerg Care 2014; 30(12): e1-5.
[http://dx.doi.org/10.1097/PEC.0000000000000320] [PMID: 25469608]
[31]
El Mazloum D, Boner A, Pietrobelli A. Accidental intravenous administration of paracetamol syrup in a child. Arch Pediatr 2016; 23(12): 1251-3.
[http://dx.doi.org/10.1016/j.arcped.2016.09.008] [PMID: 28492168]
[32]
Marín Gabriel MÁ, Ortiz Movilla R, Muñoz Labián C, et al. Accidental overdose of enoxaparin in a newborn. Arch Argent Pediatr 2018; 116(6): e762-4.
[PMID: 30457732]
[33]
Gillani SW, Gulam SM, Thomas D, et al. Role and services of a pharmacist in the prevention of medication errors: A systematic review. Curr Drug Saf 2021; 16(3): 322-8.
[http://dx.doi.org/10.2174/1574886315666201002124713] [PMID: 33006539]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy